Nexium IV

Nexium IV

esomeprazole

Manufacturer:

AstraZeneca

Distributor:

Zuellig
/
Four Star
Concise Prescribing Info
Contents
Esomeprazole Na
Indications/Uses
Treatment of GERD w/ esophagitis &/or severe symptoms of reflux. Healing of gastric ulcers associated w/ NSAID therapy. Prevention of gastric & duodenal ulcers associated w/ NSAID therapy in patient at risk. Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.
Dosage/Direction for Use
Gastric antisecretory treatment when the oral route is not possible Patient who cannot take oral medication 20-40 mg once daily. Patients w/ reflux esophagitis 40 mg once daily. Patient treated symptomatically for reflux disease 20 mg once daily. Healing of gastric ulcers associated w/ NSAID therapy & prevention of gastric & duodenal ulcer associated w/ NSAID therapy 20 mg once daily. Prevention of rebleeding of gastric & duodenal ulcers 80 mg as bolus infusion over 30 min, followed by 8 mg/hr continuous IV infusion over 3 days (72 hr) followed by oral acid suppression therapy.
Contraindications
Hypersensitivity to esomeprazole or to substituted benzimidazoles. Co-administration w/ nelfinavir.
Special Precautions
Exclude gastric malignancy before treatment. Increased risk of gastrointestinal infections; co-administration w/ atazanavir; concomitant use w/ clopidogrel. Patients w/ reduced body stores or risk factors for reduced vit B12 absorption; patients at risk of osteoporosis. Severe hypomagnesemia, especially for patients expected to be on prolonged treatment or take other medications that may cause hypomagnesemia. Severe renal & hepatic impairment. Pregnancy & lactation.
Adverse Reactions
Headache; abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting; administration site reactions.
Drug Interactions
Decreased absorption of ketoconazole, itraconazole & erlotinib. Increased absorption of digoxin. Decreased serum levels of atazanavir & nelfinavir. Increased plasma conc of diazepam, citalopram, imipramine, clomipramine & phenytoin. Increased Cmax & AUC of cilostazol & cisapride. Elevated INR w/ warfarin & other coumarine derivatives. Decreased exposure to the active metabolite of clopidogrel. Decreased serum levels w/ CYP2C19 or CYP3A4 inducers (eg, rifampicin & St. John's wort).
MIMS Class
Antacids, Antireflux Agents & Antiulcerants
ATC Classification
A02BC05 - esomeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Presentation/Packing
Form
Nexium IV powd for inj 40 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in